Navigation Links
Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
Date:2/26/2008

hase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of gout. The Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, is in a Phase 1 study in advanced cancer patients and is being investigated for the treatment of inflammatory diseases. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806, RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
11. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 “Nature has ... the features that we desire in optical design,” said ... Montana State University. “As we explore surfaces and structures ... those lessons were presented in San Diego in August ... Light in Nature ” chaired by Shaw and Rongguang ...
(Date:9/16/2014)... 2014 --The emerging field of molecular electronics could ... level, enabling the construction of tiny circuits from ... molecules would take on the roles currently played ... team of researchers from five Japanese and Taiwanese ... in small-scale electronics: a molecule called picene. In ...
(Date:9/16/2014)... , Sept. 16, 2014 Cardioxyl Pharmaceuticals, ... compound has been shown to be effective in animal ... an alternative to intravenous infusions that could pave the ... data were presented yesterday at the Heart Failure Society ... in Las Vegas . ...
(Date:9/16/2014)... 2014   Synthetic Biologics, Inc. (NYSE ... biologic and drug programs targeting specific pathogens that ... of the Company,s Investor Day in ... bowel syndrome (IBS) program, including its novel, oral ... In the keynote presentation, Mark Pimentel , ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... ... and Roles , ... Canberra, Australia (Vocus) October 27, 2009 -- Global food security, which is increasingly being ... and executed public and private partnerships, William S. Niebur , vice president – ...
... Oct. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ... that it has been granted its 33rd U.S. ... Resistant Neoplastic Cells With a Virus." The patent ... with currently approved chemotherapeutic agents to treat patients ...
... Oct. 27 Precision Antibody(TM) has been selected ... National Cancer Institute (NCI),s Clinical Proteomic Technologies for Cancer ... standardizing the quality of monoclonal antibody reagents available for ... result of a third solicitation for contract proposals from ...
Cached Biology Technology:Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 2Public-Private Partnerships Key to Achieving Global Food Security, Says DuPont Leader 3Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 2Precision Antibody Wins Contract to Develop 'Gold Standard' Antibodies as Part of National Cancer Institute's Clinical Proteomics Technologies for Cancer (CPTC) Initiative 3
(Date:9/16/2014)... 2014)The North American Menopause Society (NAMS) has published ... of midlife womenon everything from hot flashes to ... Menopause Society Recommendations for Clinical Care of Midlife ... journal Menopause . This is the first, ... of midlife women freely available to all clinicians ...
(Date:9/16/2014)... September 13, 2014. The fire is human-caused and ... acres in size and is mostly being fueled by ... Monday night due to higher humidity. Yesterday (8/15), ... to construct a fireline on the West and North sides ... the fire: , 7 20-person Crews, 4 Hot Shot Crews, ...
(Date:9/16/2014)... has its own bacterial identity. That,s the conclusion of ... who studied the genetic fingerprints of bacteria on 57 ... "This study demonstrates for the first time that host ... strategies possess very different microbial communities on their leaves," ... researcher in the UO,s Institute of Ecology and Evolution ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2
... of Leicester have identified for the first time a new ... in our blood following a meal. They have ... to maintain correct blood sugar levels. The breakthrough was ... by Professor Andrew Tobin, Professor of Cell Biology, who is ...
... of many countries in Europe and Asia. Great Tits ... long been known individuals vary considerably in their willingness to ... or "proactive" are quick explorers and are comparatively aggressive, ... differences are at least in part genetically determined and as ...
... be able to receive more effective, personalized treatments for ... cancer biology, experts will say at the Cancer Biology ... Medical Oncology (ESMO) in Nice this week. ... transformation, governments, pharmaceutical companies and doctors urgently need to ...
Cached Biology News:Bird-brained? Birds' personalities are correlated with their hormone levels 2New strategies for cancer drug development urgently needed 2New strategies for cancer drug development urgently needed 3
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
... SuperScript™ II RNase H- Reverse Transcriptase ... SuperScript™ RNase H- RT. It is a ... strand from single-stranded RNA DNA or an ... by the introduction of point mutations rather ...
... Array CGH Genomic Labeling Systems are a ... of genomic DNA samples for array-based Comparative ... and direct labeling formats, the BioPrime Plus ... flexible solution to your genomic labeling needs. ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: